Meeting
2016 ASCO Annual Meeting
Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK.
Authors
Sean David Reiff
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Sean David Reiff , Daphne Guinn , Rose Mantel , Lisa Smith , Carolyn Cheney , Amy J. Johnson , John C. Byrd , Jennifer Ann Woyach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7530)
DOI
10.1200/JCO.2016.34.15_suppl.7530
Abstract #
7530
Poster Bd #
86
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK cell-mediated cytotoxicity.
First Author: Narendiran Rajasekaran
Poster
2020 ASCO Virtual Scientific Program
Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab.
First Author: Paola Ghione
Poster
2023 ASCO Annual Meeting
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
First Author: Loretta J. Nastoupil
Poster
2020 ASCO Virtual Scientific Program
Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
First Author: Jeff P. Sharman